

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OW nucleic - nucleic search, using sw model

Run on: September 17, 2003, 16:20:15 ; Search time 310.324 Seconds
(without alignment)
13909.353 Million cell updates/sec

Title: US-10-026-106E-7

Perfect score: 1599

Sequence: 1 aagcgcatg9cg9gccccga.....acatccacgcagatcgatg 1599

Scoring table: IDENTITY NUC
Gapop 10_0, Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: N_Geneseq_13Jun03.*

1: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT.*
2: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT.*
3: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT.*
4: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT.*
5: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT.*
6: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT.*
7: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT.*
8: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT.*
9: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT.*
10: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT.*
11: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT.*
12: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT.*
13: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT.*
14: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT.*
15: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT.*
16: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT.*
17: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT.*
18: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT.*
19: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT.*
20: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT.*
21: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT.*
22: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001.DAT.*
23: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT.*
24: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT.*
25: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1549.4	96.9	1563	ABO73078	Human zcytor19 enc
2	1549.4	96.9	1563	ABO50487	Human zcytor19 rec
3	1554.2	84.7	1476	ABO73068	Human zcytor19 enc
4	1554.2	84.7	1476	ABO50485	Human zcytor19 rec
5	1086.8	68.0	1560	ABO73085	Human zcytor19 deg
6	916.2	57.3	24	ABO73069	Human zcytor19 deg
7	609.4	38.1	1922	ABO73089	MBP and zcytor19 f
8	607.4	38.0	1422	ABO73080	Zcytor19 and Fc4 f

9	498	31.1	673	24	ABO73079	Human truncated so
10	498	31.1	674	25	ABO50488	Human zcytor19 tru
11	498	31.1	704	24	ABD35324	Human (DNX) interf
12	351.2	22.0	633	24	ABO73086	Human zcytor19 deg
13	335.4	21.0	374	22	AAE64460	Novel human polynu
14	165	10.3	392	22	AAE65622	Novel human polynu
15	163.4	10.2	382	22	AAE65522	Novel human polynu
16	128	8.0	634	22	AAE65572	Human colon cancer
17	53.4	3.3	347	22	AAE65707	Human immune/haema
18	48.8	3.1	1458	22	AAE65622	Human immune/haema
19	44.4	2.8	1458	22	AAE65625	Human immune/haema
20	44.4	2.8	3112	24	ABE76526	CDNA encoding huma
21	44.4	2.8	3115	22	ABO80672	Human membrane-cyp
22	44.4	2.8	3115	22	AAE99569	Human protein enco
23	44.4	2.8	3142	22	AAE28099	Human membrane-cyp
24	44.4	2.8	3147	20	AAE87815	Tumour antigen det
25	44.4	2.8	3147	22	AAE13113	Human membrane-cyp
26	44.4	2.8	3147	22	AAE13155	Human membrane-cyp
27	44.4	2.8	3147	22	AAE23601	Human TADG-15 codi
28	44.4	2.8	3147	22	AAE23609	Human TADG-15 anti
29	44.4	2.8	3147	24	AAE53444	Type II transmembr
30	44.4	2.8	3147	24	AAE53445	Type II transmembr
31	44.4	2.8	3147	25	ABE258500	Transmembrane seri
32	44.4	2.8	3147	25	ABE258501	Transmembrane seri
33	44.4	2.8	3147	25	ABE22450	Human membrane-cyp
34	44.4	2.8	3147	25	ABE22451	Human membrane-cyp
35	44.4	2.8	3147	25	ABD47180	Human membrane-cyp
36	44.4	2.8	3147	25	ABD47181	Human membrane-cyp
37	44.4	2.8	3147	25	ABD47225	Human membrane-cyp
38	44.4	2.8	3149	21	AAE88493	Human membrane-cyp
39	44.4	2.8	3152	22	AAE88493	Human membrane-cyp
40	44.4	2.8	3159	21	AAE37431	Human membrane-cyp
41	44.4	2.8	3413	23	AAE85629	Human membrane-cyp
42	42.2	2.6	971	21	AAE58883	Human membrane-cyp
43	42.2	2.6	3780	22	AAE13823	Human membrane-cyp
44	42.2	2.6	4174	22	AAE13821	Human membrane-cyp
45	42	2.6	2900	22	AAE23602	Human membrane-cyp

ALIGNMENTS

RESULT 1	ABO73078	standard, cDNA, 1563 bp.
ID	ABO73078	
AC	ABO73078	
DT	25-SEP-2002 (first entry)	
XX	Human zcytor19 encoding cDNA SEQ ID NO:18.	
XX	Human; zcytor19, cytokine receptor; immunosuppressive; cytostatic; antitumour; antitachytic; neuroprotective; antinflammatory; antidiabetic; nephroprotective; dermatological; anti-HIV; haemostatic; vaccine; immune system; T-cell specific leukemia; lymphoma; lupus; autoimmune disease; rheumatoid arthritis; multiple sclerosis; HIV; diabetes mellitus; inflammatory bowel disease; Crohn's disease; asthma; immunologic renal disease; glomerulonephritis; vasculitis; polyarteritis; mesangiolipolytic disease; chronic lymphocytic leukemia; bronchitis; secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma; haemolytic uraemic syndrome; renal neoplasm; urological neoplasm; emphysema; chronic airway disease; chromosome 1; chromosome 1p36.11; gene; ss.	
XX	Human sapiens.	
OS	Human sapiens.	
XX	Key	Location/Qualifiers
FT	CDS	1..1563
FT	FT	/*tag- a
FT	FT	/*product= "zcytor19"
FT	FT	1..60
FT	FT	/*tag- b
FT	FT	sig_peptide

FT	mat_peptide	61..1560
FT	/+cag= C	
FT	/product= "mature zcytor19"	
XX		
PN	NO200244209-A2.	
PD	06-JUN-2002.	
XX		
PZ	28-NOV-2001; 2001WO-US44808.	
PR	28-NOV-2000; 2000US-253561P.	
PR	07-FEB-2001; 2001US-267211P.	
PA	(ZYMO) ZYMOGENETICS INC.	
PI	Presnell SR, Xu W, Novak JE, Whitmore TE, Grant FU,	
DR	WPI, 2002-527700/56.	
XX	P-PDB; ABBB1643.	
PT	Novel Zcytor19 polypeptides and polynucleotides useful for stimulating	
PS	immune responses in animals for producing antibodies, and for treating	
XX	autoimmune diseases, leukemia and asthma -	
XX	ClaIn 2; Page 174-177; 200pp; English.	
CC	The present invention describes an isolated human zcytor19 protein (I),	
CC	and truncated zcytor19 proteins. (I) has immunosuppressive, cytostatic,	
CC	antirheumatic, antiarthritic, neuroprotective, antiinflammatory,	
CC	antiidiabetic, nephrotoxic, dermatological, anti-HIV and haemostatic	
CC	activities, and can be used in vaccines. (I) or an antibody binding (I)	
CC	can be used for suppressing the immune system for reducing rejection of	
CC	tissue or organ transplants and grafts and for treating T-cell specific	
CC	leukemias or lymphomas and autoimmune diseases including rheumatoid	
CC	arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel	
CC	disease and Crohn's disease. The antibodies can also be used for treating	
CC	immunologic renal diseases, glomerulonephritis, mesangioliproliferative	
CC	disease, chronic lymphocytic leukaemia, secondary glomerulonephritis or	
CC	vascularitis associated with lupus, polyarteritis, scleroderma, HIV-related	
CC	diseases, amyloidosis and haemolytic uremic syndrome. (I) and the	
CC	antibodies can also be used for renal or urological neoplasms and	
CC	multiple myeloma, asthma, bronchitis, emphysema and other chronic	
CC	airway diseases. Human zcytor19 is located to chromosome 1, more	
CC	specifically to chromosome 1p36.11. The present sequence encodes a human	
CC	zcytor19 protein from the present invention.	
XX		
SO	Sequence 1563 BP; 335 A; 468 C; 471 G; 289 T; 0 other;	
Query Match	96.3%; Score 1549.4; DB 24; Length 1563;	
Best Local Similarity	99.9%; Pred. No. 0;	
Matches 1561; Conservative	0; Mismatches 1; Indels 1; Gaps 1	
QY	7 ATGGGAGGAGCGCAGACGCTGGAGCCCCCTGTGCTTGTGCCTGTCACAGGCGCTCAAGG	66
Db	1 ATGGGAGGAGCGCAGACGCTGGAGCCCCCTGTGCTTGTGCCTGTCACAGGCGCTCAAGG	60
QY	67 AGGCCCGCTTGAGCCCCCTGTGCTTGTGCCTGTCACAGGCGCTCAAGGCGCTCAAGG	126
Db	61 AGGCCCGCTTGAGCCCCCTGTGCTTGTGCCTGTCACAGGCGCTCAAGGCGCTCAAGG	120
QY	127 CTGACATGAGCTCCAGAGGCTTTGGCAAACCCAGGATGTGAACCTATTGTTGGCC-ATCAG	185
Db	121 CTGACATGAGCTCCAGAGGCTTTGGCAAACCCAGGATGTGAACCTATTGTTGGCTATCAG	180
QY	186 AGCTCTCCACCCTGTAGAAGGTGGCGCAATGTGAAGATGTGCGGAAACCAAGACTG	245
Db	181 AGCTCTCCACCCTGTAGAAGGTGGCGCAATGTGAAGATGTGCGGAAACCAAGACTG	240
QY	246 CATATTTCAATGATGCTCTGAAGAAAGAGAACCTGTACAACAAGTTCAAGGACGCGTG	305
Db	241 CATATTTCAATGATGCTCTGAAGAAAGAGAACCTGTACAACAAGTTCAAGGACGCGTG	300
QY	306 CGAAGGTTTTCTCCACAGCTCAAGTCCCCTGTGGGTGAGTCCGAATTAACCTGATTAATT	365

D	301	CGACGGTTTCTTCCAGCTCCAAATCCCCCTGGGTGAGTCCGAATACCTGGATTACCTT	360
Q	366	TTTGAATGGAGCCGCCCCACCTGTCTGTGTGTCAACCAGACGGAGAGATCTGTACT	425
D	361	TTTAAATGGAGCCGCCCCCACTGTCTGTGTGTCTCAACCAGACGGAGAGATCTGTACT	420
Q	426	GCCAAATGCCAGTACCACTGTGCCCCCTGTGATGCCCCCACTGGATCTGAAGTATGAGGTG	485
D	421	GCCAAATGCCAGTACCACTGTGCCCCCTGTGATGCCCCCACTGGATCTGAAGTATGAGGTG	480
Q	486	GCAATTCGGAAGGAGGGGGCCGGAACAAGACCTATTTCAGATCACTGCCCATGGCCAG	545
D	481	GCAATTCGGAAGGAGGGGGCCGGAACAAGACCTATTTCAGATCACTGCCCATGGCCAG	540
Q	546	CCAATCCAGATCACTTCTCAGCCAGCTGCCAGGAACACACTGCTCTCAGTCCAGAAC	605
D	541	CCAATCCAGATCACTTCTCAGCCAGCTGCCAGGAACACACTGCTCTCAGTCCAGAAC	600
Q	606	ATTACACGTTCAAGTGTCCCGAAATACAGAGATTCTCTAAGCCCACTGCTCTTGCTG	665
D	601	ATTACACGTTCAAGTGTCCCGAAATACAGAGATTCTCTAAGCCCACTGCTCTTGCTG	660
Q	666	GAGTCCCAGAAAGCCAACTGGGCTTTTCTGTGTGTGCCATGCTTCTGATACGTGCTTA	725
D	661	GAGTCCCAGAAAGCCAACTGGGCTTTTCTGTGTGTGCCATGCTTCTGATACGTGCTTA	720
Q	726	GTAATTGCCGAGGGGGTGTATCTGGAGAACCTCATGGGAAACCCCTGTTCACGCG	785
D	721	GTAATTGCCGAGGGGGTGTATCTGGAGAACCTCATGGGAAACCCCTGTTCACGCG	780
Q	786	GCAAAATGCGACGGGGCTTGGACTTTTCTGACACACACACCTGTGGGAACCTTTTCA	845
D	781	GCAAAATGCGACGGGGCTTGGACTTTTCTGACACACACACCTGTGGGAACCTTTTCA	840
Q	846	CCCAAGCAGACCAAGATCCGTGAATGACTTGTCTCTGTCCCAAAAGAACTGACAGA	905
D	841	CCCAAGCAGACCAAGATCCGTGAATGACTTGTCTCTGTCCCAAAAGAACTGACAGA	900
Q	906	GGGGTCAAGGCCGACCTCGATGACAGGGCCCAAGCCACCAAGACAGAAATGAAGAAG	965
D	901	GGGGTCAAGGCCGACCTCGATGACAGGGCCCAAGCCACCAAGACAGAAATGAAGAAG	960
Q	966	GACCTTGCAGAGGAGAGAGAGAGAGAGAGAGAGACAGAAATGGGCTCACTTC	1025
D	961	GACCTTGCAGAGGAGAGAGAGAGAGAGAGAGAGACAGAAATGGGCTCACTTC	1020
Q	1026	CAGCCCTTACATTGAACCACTTTCTTTCTGTGGGCAAGACCAAGGCTCAAGGGCACTG	1085
D	1021	CAGCCCTTACATTGAACCACTTTCTTTCTGTGGGCAAGACCAAGGCTCAAGGGCACTG	1080
Q	1086	GAGGCTGTGGGTGAGACTCAAGGAGGGCCAGGGCTCTGTGTCCCAAGCAAGGCTCC	1145
D	1081	GAGGCTGTGGGTGAGACTCAAGGAGGGCCAGGGCTCTGTGTCCCAAGCAAGGCTCC	1140
Q	1146	TTGTCTTGGGATTTTTCAGACAGAAAGTGGGCACTGTGACCTCTCTGTGGGACAG	1205
D	1141	TTGTCTTGGGATTTTTCAGACAGAAAGTGGGCACTGTGACCTCTCTGTGGGACAG	1200
Q	1206	GCTGGGTCTCTTGAGCTAATTTGGCTGAAGAGGGCCAGGCAAGGGCCGGGTGGGATGG	1265
D	1201	GCTGGGTCTCTTGAGCTAATTTGGCTGAAGAGGGCCAGGCAAGGGCCGGGTGGGATGG	1260
Q	1266	CACCAAGAAATCTCTCCCAACAACCTGAATTCCTCAAGAGACTGGGGTTTCTGGAAGGCT	1325
D	1261	CACCAAGAAATCTCTCCCAACAACCTGAATTCCTCAAGAGACTGGGGTTTCTGGAAGGCT	1320
Q	1326	CCAGAAATACCTCTCTCTCTGGGCACTGTGGGCACTTACCAACCGAGCCGAATCTG	1385
D	1321	CCAGAAATACCTCTCTCTCTGGGCACTGTGGGCACTTACCAACCGAGCCGAATCTG	1380
Q	1386	GTCCTGTGGGGAACCCCAAGTTTCTTTCAACACTGACCTTCTGTGGGAACCACTCT	1445

Db	1381	GTCCCTGGGGGACCCCCAGTTTCTCTTCAGACACTGACCTTTCTGCTGGGAAAGCAGACCTT	1440
Qy	1446	GAGGAGGAAAGAGAGGCGGAGGAAATCAGAAATTTAGGACACAGCATGCGGCGACTGGGGG	1505
Db	1441	GAGGAGGAAAGAGAGGCGGAGGAAATCAGAAATTTAGGACACAGCATGCGGCGACTGGGGG	1500
Qy	1506	GCTGAGAGCACCCAGAGGACCGAGGACGAGGAGCGGCGGCGCATTTGGGGCATTCATGCGCAG	1565
Db	1501	GCTGAGAGCACCCAGAGGACCGAGGACGAGGAGCGGCGGCGCATTTGGGGCATTCATGCGCAG	1560
Qy	1565	TGA 1568	
Db	1561	TGA 1563	
RESULT 2			
AD50487	ID	AD50487 standard, cDNA, 1563 BP.	
AC	XX		
AD50487;	XX		
24-MAR-2003	XX	(first entry)	
Human zcytor19 receptor cDNA.	XX		
Human; leukemia; carcinoma; acquired immune deficiency syndrome; AIDS; melanoma; Kaposi's sarcoma; multiple myeloma; non-Hodgkin's lymphoma; hepatitis; infection; myocarditis; blood vessel formation; gene therapy; growth regulation; developmental process; immunotherapy; zcytor19; gene; receptor; ss.	XX		
Homo sapiens.	OS		
Key	XX		
CDS	XX		
	XX	Location/Qualifiers	
	XX	1..1563	
	XX	/*tag= a	
	XX	/product= "Human zcytor19 receptor"	
	XX	1..60	
	XX	/*tag= b	
	XX	61..1560	
	XX	/*tag= c	
	XX	/product= "Mature human zcytor19 receptor"	
W0200286087-A2.	XX		
31-OCT-2002.	XX		
19-APR-2002; 2002W0-US12887.	XX		
20-APR-2001; 2001US-285408P.	XX		
20-APR-2001; 2001US-285424P.	XX		
25-APR-2001; 2001US-286482P.	XX		
29-JUN-2001; 2001US-0895834.	XX		
22-OCT-2001; 2001US-341050P.	XX		
22-OCT-2001; 2001US-341105P.	XX		
(ZYMO) ZYMOGENETICS INC.	XX		
Shepherd PO, Fox BA, Klucher KM, Taft DW, Kindsvogel WR;	XX		
WPI; 2003-093122/08.	XX		
P-PSDB; AA832768.	XX		
New zcyto20, zcyto21, zcyto22, zcyto24 and zcyto25 polypeptides and polynucleotides useful for treating leukemia, carcinoma, malignant melanoma, AIDS-related Kaposi's sarcoma, myeloma, non-Hodgkin's lymphoma, hepatitis and infections	XX		
The invention relates to zcyto20, zcyto21, zcyto22, zcyto24 and zcyto25 polypeptides and polynucleotides. Sequences of the invention are useful for treating hairy cell leukemia, renal cell or basal cell carcinoma,	XX		
Example 30; Page 147-148; 160pp; English.	XX		

[illegible]

Oy		906	GGGAGTCAGGCCCAACGCCTCCAGATCAGGGCCCCCAGCACCCCAAACAGACATGTGAAGAAG	965
Db		901	GGGATCAGGCCCAACCGCTCGATGACTAGGGCCCCCAGCACCCCAAACAGACATGTGAAGAAG	960
Oy		966	GACCTTGCACAGACGACAAAGAGAGAGAGATGAGAGAGACACAGAAATGAGCGTCAGCTTC	1025
Db		961	GACCTTGCACAGACGACAAAGAGAGAGATGAGAGAGACACAGAAATGAGCGTCAGCTTC	1020
Oy		1026	CAGCCCTACATTGAAACACCTCTCTTCTCTGGGGCAAGAACACAGAGCTCCAGGGCACCTGG	1085
Db		1021	CAGCCCTACATTGAAACACCTCTCTTCTCTGGGGCAAGAACACAGAGCTCCAGGGCACCTGG	1080
Oy		1086	GAGCGCTGTGGTGTTGGAGACTCAGGGAGAGGCCAAGGGGCTCCCTGTGTGCCAAGAAAGCTCC	1145
Db		1081	GAGCGCTGTGGTGTTGGAGACTCAGGGAGAGGCCAAGGGGCTCCCTGTGTGCCAAGAAAGCTCC	1140
Oy		1146	TCTGCTTGGGATTTCTTCACACAGAACTGGGCCACACCTGTGSACTCCTCTTGGGACAGG	1205
Db		1141	TCTGCTTGGGATTTCTTCACACAGAACTGGGGCCACACCTGTGSACTCCTCTTGGGACAGG	1200
Oy		1206	GCTGGGCTCTCTGGCTAATTGGCTGAGAAAGGGCCAGGGCCAGGGGCTGGGGATGGGG	1265
Db		1201	GCTGGGCTCTCTGGCTAATTGGCTGAGAAAGGGCCAGGGCCAGGGGCTGGGGATGGGG	1260
Oy		1266	CACCAAGAAATCTCTCCACACACTGGAATATCTCCACAGSACTGGGGTTCTCGAAGAGCTCC	1325
Db		1261	CACCAAGAAATCTCTCCACACACTGGAATATCTCCAGSACTGGGGTTCTCGAAGAGCTCC	1320
Oy		1326	CCAGAAAGATAACTCTCTCTCTCTGGGCCACTGGGGCACCTTAACAACGGAGACCGAATCTG	1385
Db		1321	CCAGAAAGATAACTCTCTCTCTCTGGGCCACTGGGGCACCTTAACAACGGAGACCGAATCTG	1380
Oy		1386	GTCCTCTGGGGGACCCCCAGATTCTCTTTCACACACTGACCTGTGTGTGGAAAACAGACCT	1445
Db		1381	GTCCTCTGGGGGACCCCCAGATTCTCTTTCACACACTGACCTGTGTGTGGAAAACAGACCT	1440
Oy		1446	GAGAGGAAAGAGAGGGCAGGGAAATCAGAAATTGAGACACGGATGCGGGGACCTGGGGG	1505
Db		1441	GAGAGGAAAGAGAGGGCAGGGAAATCAGAAATTGAGACACGGATGCGGGGACCTGGGGG	1500
Oy		1506	GCTGAGACACCCACAGAGACCCAGAGACAGGGGGCCGACATTGGGGCATTAATGCGCAGG	1565
Db		1501	GCTGAGACACCCACAGAGACCCAGAGACAGGGGGCCGACATTGGGGCATTAATGCGCAGG	1560
Oy		1566	TGA 1566	
Db		1561	TGA 1563	
RESULT 3				
ABQ73068				
ID	ABQ73068 standard; cDNA; 1476 BP.			
XX	ABQ73068;			
DT	25-SEP-2002 (first entry)			
DE	Human zcytor19 encoding cDNA SEQ ID NO:1.			
XX				
Kw	Human; zcytor19; cytokine receptor; immunosuppressive; cytostatic; antiinfective; antitubercitic; neuroprotective; anti-inflamatory; antidiabetic; nephrotoxic; dermatological; anti-HIV; haemostatic; vaccine; immune system; T-cell specific leukaemia; lymphoma; lupus; autoimmune disease; rheumatoid arthritis; multiple sclerosis; HIV; diabetes mellitus; inflammatory bowel disease; Crohn's disease; asthma; immunologic renal disease; glomerulonephritis; vasculitis; polyarteritis; Kw neuropathic ulcerative disease; chronic lymphocytic leukaemia; bronchitis; Kw haemolytic uraemic syndrome; renal neoplasm; urological neoplasm; Kw empyema; chronic airway disease; chromosome 1; chromosome 1p36.11; gene; ss. Ox- Homo sapiens.			
Ox-	Homo sapiens.			

	Key	Location/Qualifiers
PH	CDS	1..1473
FT		/tag= a
FT		/product= "zcytor19"
FT	sig_peptide	1..60
FT		/tag= b
FT	mat_peptide	61..1470
FT		/tag= c
FT		/product= "mature zcytor19"
XX		
PN		WO200244209-A2.
PD		
XP		.06-JUN-2002.
PF		28-NOV-2001; 2001WO-US44808.
PR		28-NOV-2000; 2000US-253561P.
PR		07-FEB-2001; 2001US-267211P.
PA		(Zymo) ZYMOGENETICS INC.,
PI		Presnell SR, Xu W, Novak JE, Whitmore TE, Grant FU;
DR		WPI; 2002-527700/56.
DR		P-PSDB; ABB81636.
XX		
PT		Novel zcytor19 polypeptides and polynucleotides useful for stimulating
PT		immune responses in animals for producing antibodies, and for treating
PT		autoimmune diseases, leukemia and asthma -
XX		
PS		Claim 2; Page 160-163; 200pp; English.
CC		The present invention describes an isolated human zcytor19 protein (I),
CC		and truncated zcytor19 proteins. (II) has immunosuppressive, cytostatic,
CC		antihepatitic, antirheumatic, neuroprotective, anti-inflammatory,
CC		antidiabetic, nephrotropic, dermatological, anti-HIV and haemostatic
CC		activities, and can be used in vaccines. (I) or an antibody binding (I)
CC		can be used for suppressing the immune system for reducing rejection of
CC		tissue or organ transplants and grafts and for treating T-cell specific
CC		leukemia or lymphomas and autoimmune diseases including rheumatoid
CC		arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel
CC		disease and Crohn's disease. The antibodies can also be used for treating
CC		immunologic renal diseases, glomerulonephritis, mesangiolipidiferative
CC		disease, chronic lymphocytic leukemia, secondary glomerulonephritis or
CC		vesselitis associated with lupus, polyarteritis, scleroderma, HIV-related
CC		diseases, amyloidosis and hemolytic uremic syndrome. (I) and the
CC		antibodies can also be used for renal or urological neoplasms and
CC		multiple myeloma, asthma, bronchitis, emphysema and other chronic
CC		airway diseases. Human zcytor19 is located to chromosome 1, more
CC		specially to chromosome 1p35.11. The present sequence encodes a human
CC		zcytor19 protein from the present invention.
XX		
SQ		Sequence 1476 BP; 309 A; 439 C; 456 G; 272 T; 0 other;
Query Match	84.7%; Score 1354.2; DB 24; Length 1476;	
Best Local Similarity	93.9%; Pred. No. 0;	
Matches 1467; Conservative 0; Mismatches 8; Indels 88; Gaps 2		
QY	7	ATGGGCGGGGCCAGAGCGCTGGGGCCCCCTGTCTCTGTCGCTGCACAGCGCGCTCCAGG 66
Db	1	ATGGGCGGGGCCAGAGCGCTGGGGCCCCCTGTCTCTGCTCTCCTGCACAGCGCGCTCCAGG 60
QY	67	AGGCGCGCTGTGGCGCTTCCCAGAAATGTGACGTGTCTCTCCAGAACTTGACGTGTAC 126
Db	61	AGGCGCGCTGTGGCGCTTCCCAGAAATGTGACGTGTCTCTCCAGAACTTGACGTGTAC 120
QY	127	CTGACATAGGCTCCCAAGGGCTTGGAACAACCCAGAGATGTGACTATTTTGTGGCC-ATCAG 185
Db	121	CTGACATAGGCTCCCAAGGGCTTGGAACAACCCAGAGATGTGACTATTTTGTGGCTATCAG 180
QY	186	AAGCTCTCCCAACCGTAAAGCGTGGCGCAAGTGAAGAAGTGGCGGAAACCAAGACTG 245

Db 181 AGCTCTCCACCCGTAAGCGGTGGCGGAAGTGAAGAGTGTGGGGGAAACCAAGAGACTG 240
 QY 246 CTATGTTCTAATGATATGCTGTAAGAAACAGAGACTGTATACAAAGTTTAAAGGACGGGTG 305
 Db 241 CTATGTTCTAATGATATGCTGTAAGAAACAGAGACTGTATACAAAGTTTAAAGGACGGGTG 300
 QY 306 CGAGCGGTTTCTCCAGCTCCAGTCCAGTCCCTGGGTGAGTCCGAATACCTGGAATTAACCTT 365
 Db 301 CGAGCGGTTTCTCCAGCTCCAGTCCAGTCCCTGGGTGAGTCCGAATACCTGGAATTAACCTT 360
 QY 366 TTTGAAGTGAAGCGGGGCCCAACCTGTCTGGGTGCTCAACCGAGAGAGAGATCTGAGT 425
 Db 361 TTTGAAGTGAAGCGGGGCCCAACCTGTCTGGGTGCTCAACCGAGAGAGATCTGAGT 420
 QY 426 GCGAATGCCAGCTACAGCTGCCCCCTGTGATGCCCACTGGAATCTGAAGTATGAGTGT 485
 Db 421 GCGAATGCCAGCTACAGCTGCCCCCTGTGATGCCCACTGGAATCTGAAGTATGAGTGT 480
 QY 486 GCATTCTGGAAGAGGGGGCGGGAACAAGACCTATTTCAGTCACTCCCAATGGCCAG 545
 Db 481 GCATTCTGGAAGAGGGGGCGGGAACAAGACCTATTTCAGTCACTCCCAATGGCCAG 540
 QY 546 CCAATCTCAGATCACTCTCAGCAAGCTGCGAGCAACAACATGCTCAGTGCAGAACCC 605
 Db 541 CCAATCTCAGATCACTCTCAGCAAGCTGCGAGCAACAACATGCTCAGTGCAGAACCC 600
 QY 606 ATCTACAGCTTCAAGTCTCCGAATAACAGCAAGTTCTCTAAGGCCACCTGCTTCTGCTG 665
 Db 601 ATCTACAGCTTCAAGTCTCCGAATAACAGCAAGTTCTCTAAGGCCACCTGCTTCTGCTG 660
 QY 666 GAGGTCCCAAGAGGAACTGGGCTTCTCTGTGTGCTGCAATGCTTCTGATATCTGTTA 725
 Db 661 GAGGTCCCAAGAGGAACTGGGCTTCTCTGTGTGCTGCAATGCTTCTGATATCTGTTA 720
 QY 726 GTAAATGGCCGAGGGGGTGTGATCTGGAAGACCTCATGGGGAACCCCTGTTTCAGCGG 785
 Db 721 GTAAATGGCCGAGGGGGTGTGATCTGGAAGACCTCATGGGGAACCCCTGTTTCAGCGG 780
 QY 786 GCAAGATGCAAGGGGGCTGGACCTTTTCTGAGACACACACCTGTGGCAACCTTTCAG 845
 Db 781 GCAAGATGCAAGGGGGCTGGACCTTTTCTGAGACACACACCTGTGGCAACCTTTCAG 840
 QY 846 CCCAGCAGACCAAGTCCGTGAATGAATTGTTCTGTCTCCCAAAAGAACTGACAGA 905
 Db 801 -----GGAACAGACAGA 813
 QY 906 GGGGTCAAGGCCGAGCTGAGTCAAGGGGCCCAAGCCCAACAGACAGATGGAAGAG 965
 Db 814 GGGGTCAAGGCCGAGCTGAGTCAAGGGGCCCAAGCCCAACAGACAGATGGAAGAG 873
 QY 966 GACCTTGCAGAGCAGAAAGAGAGAGATGAGAGACACAGAAATGAGCTCAGCTTC 1025
 Db 874 GACCTTGCAGAGCAGAAAGAGAGAGATGAGAGACACAGAAATGAGCTCAGCTTC 933
 QY 1026 CAGCCCTACATGTAACCACTTCTTCCCTGGGGGCAAGAGCCAGGCTCCAGAGGCACTG 1085
 Db 934 CAGCCCTACATGTAACCACTTCTTCCCTGGGGGCAAGAGCCAGGCTCCAGAGGCACTG 993
 QY 1086 GAGGTGTGGGTGTGAATCTCAGAGAGAGCCAGAGGCTCTCTGTGCTCCAAAGCAAGCTTC 1145
 Db 994 GAGGTGTGGGTGTGAATCTCAGAGAGAGCCAGAGGCTCTCTGTGCTCCAAAGCAAGCTTC 1053
 QY 1146 TCTGCTTGGGATCTTCTCAGAGAGCTGGGCAAGCTGTGAGCTCTCTCTGGGACAGG 1205
 Db 1054 TCTGCTTGGGATCTTCTCAGAGAGCTGGGCAAGCTGTGAGCTCTCTCTGGGACAGG 1113
 QY 1206 GCTGGGTCTCTGCTAATTTGGGTGAAGAGGGGCCAGAGGCGGGTGGGATGGG 1265
 Db 1114 GCTGGGTCTCTGCTAATTTGGGTGAAGAGGGGCCAGAGGCGGGTGGGATGGG 1173
 QY 1266 CACCAAGAAATCTCTCCACCACTGAATTTCTCAAGAGCTCGGGTTTCTTGAAGAGCTC 1325
 Db 1174 CACCAAGAAATCTCTCCACCACTGAATTTCTCAAGAGCTCGGGTTTCTTGAAGAGCTC 1233

QY 1326 CCAGAGATTAACCTTCTCTCTGGGCACTTGGGCACTTACCAACCGAGCCGAATCTG 1385
 Db 1234 CCAGAGATTAACCTTCTCTCTGGGCACTTGGGCACTTACCAACCGAGCCGAATCTG 1293
 QY 1386 GTCCCTGGGGGAGACCCCAAGTTTCTTTCAGACATGACCTTGTGGGGAAGAGCCCT 1445
 Db 1234 GTCCCTGGGGGAGACCCCAAGTTTCTTTCAGACATGACCTTGTGGGGAAGAGCCCT 1353
 QY 1446 GAGAGAGAGAGAGAGGCGAGGATCAGAAATTGAGACAGCGATGCGGCGAGCTGAGG 1505
 Db 1354 GAGAGAGAGAGAGAGGCGAGGATCAGAAATTGAGACAGCGATGCGGCGAGCTGAGG 1413
 QY 1506 GCTGAGAGACCCAGAGAGCCAGAGACAGGGGCGGACATTTGGGCACTTACATGAGCAG 1565
 Db 1414 GCTGAGAGACCCAGAGAGCCAGAGACAGGGGCGGACATTTGGGCACTTACATGAGCAG 1473
 QY 1566 TGA 1568
 Db 1474 TGA 1476
 RESULT 4
 AAD50485
 ID AAD50485 standard; cDNA, 1476 BP.
 XX
 AC AAD50485;
 XX
 DT 24-MAR-2003 (first entry)
 XX
 DE Human zcytor19 receptor variant cDNA.
 XX
 KW Human; leukemia; carcinoma; acquired immune deficiency syndrome; AIDS; melanoma; Kaposi's sarcoma; multiple myeloma; non-Hodgkin's lymphoma; hepatitis; infection; myocarditis; blood vessel formation; gene therapy; growth regulation; developmental process; immunotherapy; zcytor19; gene; receptor; variant; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 1..1476
 FT /+tag= a
 FT /product= "Human zcytor19 receptor variant"
 FT sig_peptide 1..60
 FT /+tag= b
 FT mat_peptide 61..1473
 FT /+tag= c
 FT /product= "Mature human zcytor19 receptor variant"
 XX
 PN MO200286087-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 19-APR-2002; 2002W0-US12887.
 XX
 PR 20-APR-2001; 2001US-285408P.
 PR 20-APR-2001; 2001US-285424P.
 PR 25-APR-2001; 2001US-286482P.
 PR 29-JUN-2001; 2001US-0895834.
 PR 22-OCT-2001; 2001US-341050P.
 PR 22-OCT-2001; 2001US-341105P.
 XX
 PA (ZYMO) ZYMOGENETICS INC.
 XX
 PI Sheppard PO, Fox BA, Klucher KM, Taft DW, Kinsavogel WR,
 DR WPI; 2003-093122/08.
 DR P-PSDB; AAB32766.
 XX
 XX New zcyto20, zcyto21, zcyto22, zcyto24 and zcyto25 polypeptides and
 PT polynucleotides useful for treating leukemia, carcinoma, malignant
 PT melanoma, AIDS-related, Kaposi's sarcoma, myeloma, non-Hodgkin's

KM mesangiolipoferrative disease; chronic lymphocytic leukemia; bronchitis;
 KM secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma;
 KM haemolytic uraemic syndrome; renal neoplasm; urological neoplasm;
 KM emphysema; chronic airway disease; chromosome 1; chromosome 1p36.11;
 KM gene; 88.
 OS Homo sapiens.
 XX WO200244209-A2.
 XX 06-JUN-2002.
 XX 28-NOV-2001; 2001NO-US44808.
 XX 28-NOV-2000; 2000US-253561P.
 XX 07-FEB-2001; 2001US-267211P.
 XX (ZYMO) ZYMOGENETICS INC.
 XX Presnell SR, Xu W, Novak JE, Whitmore TE, Grant FJ;
 DR WPI; 2002-527700/56.
 XX
 PT Novel Zcytoris polypeptides and polynucleotides useful for stimulating
 PT immune responses in animals for producing antibodies, and for treating
 PT autoimmune diseases, leukemia and asthma -
 XX
 PS Disclosure; Page 187-188; 200pp; English.
 XX
 CC The present invention describes an isolated human zcytoris protein (1),
 CC and truncated zcytoris proteins. (1) has immunosuppressive, cytostatic,
 CC antineoplastic, antitachytic, neuroprotective, anti-inflammatory,
 CC antidiabetic, nephrotropic, dermatological, anti-HIV and haemostatic
 CC activities, and can be used in vaccines. (1) or an antibody binding (1)
 CC can be used for suppressing the immune system for reducing rejection of
 CC tissue or organ transplants and grafts and for treating T-cell specific
 CC leukemias or lymphomas and autoimmune diseases including rheumatoid
 CC arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel
 CC disease and Crohn's disease. The antibodies can also be used for treating
 CC immunologic renal diseases, glomerulonephritis, mesangiolipoferrative
 CC disease, chronic lymphocytic leukemia, secondary glomerulonephritis or
 CC vasculitis associated with lupus, polyarthritis, scleroderma, HIV-related
 CC diseases, amyloidosis and haemolytic uraemic syndrome. (1) and the
 CC antibodies can also be used for renal or urological neoplasms and
 CC multiple myelomas, asthma, bronchitis, emphysema and other chronic
 CC airway diseases. Human zcytoris is located to chromosome 1, more
 CC specifically to chromosome 1p36.11. The present sequence represents a
 CC degenerate nucleotide sequence encoding a human zcytoris protein from
 CC the present invention.
 CC
 SO Sequence 1560 BP; 221 A; 209 C; 286 G; 173 T; 671 other;
 Query Match 68.0%; Score 1086.8; DB 24; Length 1560;
 Best Local Similarity 57.0%; Pred. No. 2.1e-271;
 Matches 888; Conservative 355; Mismatches 315; Indels 1; Gaps 1;

DB 241 YTTGTGWSNATANTGTGTTAAABARCAAGAYTTTAAVAAATTAAAGGWSNGTN 300
 QY CGAAGCGTTTCTCCAGATGAGTCCCTGGGGTGGATCGGAATACCGGATTAACCTT 365
 DB 306 CGAAGCGTTTCTCCAGATGAGTCCCTGGGGTGGATCGGAATACCGGATTAACCTT 365
 DB 301 MGNACNGTWSNCCNMSWSNBARNSCCCTGGGTTGAGWSNBARATYTTGATTAATYTN 360
 QY 366 TTTGAAGTGAAGCGGCGCCCACTGTCTGTGGTCTCAACAGACGAGAGATCTGAGT 425
 DB 361 TTTGAAGTGAAGCGGCGCCCACTGTCTGTGGTCTCAACAGACGAGAGATCTGAGT 425
 QY 426 GCCAATGCCAGTACAGTACGCTCCGATGAGCCCACTGAGATCTGAGATGAGG 485
 DB 421 GGNAAVGCNANTAYCARATNCCNCTGTATGCCNCTNAGATYTTAAATYAGAGTN 480
 QY 486 GCATTTGGAAGAGGGGGCGGAAAAGAACCTTATTTCAATCTCCCATGGCCAG 545
 DB 481 GCATTTGGAAGAGGGGGCGGAAAAGAACCTTATTTCAATCTCCCATGGCCAG 540
 QY 546 CCAGTCCAGATCACTCTCCAGCGAGCTGCACAGAACCACTGCTCAGTCCAGAAC 605
 DB 541 CCAGTCCAGATCACTCTCCAGCGAGCTGCACAGAACCACTGCTCAGTCCAGAAC 600
 QY 606 ATCTACAGTCAATGTCCGAAATACAGCAAGTTCTTAAGCCACTGCTCTTGTCTG 665
 DB 601 ATHTATACNTTYWSNGTNCNAAATAYWSNAAATYWSNAAACNACNTGYTYTYTN 660
 QY 666 GAGGTCCAGAGAGAACTGGCTTCTGTGTGTCTGCTGCTGCTGCTGCTGCTGCT 725
 DB 661 GAGGTCCAGAGAGAACTGGCTTCTGTGTGTCTGCTGCTGCTGCTGCTGCTGCT 720
 QY 726 GTAATTCGCGAGGGGGTGTGATCTGGAAGACCTCAAGGGGAAACCTGCTTTCAG 785
 DB 721 GTNATHGCGNCGNAGNGATNATHTGAAARACNTYTNATGAGGAAATCCGTGTTCA 780
 QY 786 GCAAAGATCCAGCGGCGCTGGAATTTCTGTGACACACACCTGTGGCACTTTCAG 845
 DB 781 GCAAAGATCCAGCGGCGCTGGAATTTCTGTGACACACACCTGTGGCACTTTCAG 840
 QY 846 CCACAGACAGAGAGTCCGTAATGATGATCTGCTGCTGCTGCTGCTGCTGCTGCT 905
 DB 841 CCACAGACAGAGAGTCCGTAATGATGATCTGCTGCTGCTGCTGCTGCTGCTGCT 900
 QY 906 GGGGTCCAGCGGAGCTGAGTCAAGGCGCCCAAGCAACCAAGACAAGATGAGAG 965
 DB 901 GGGGTCCAGCGGAGCTGAGTCAAGGCGCCCAAGCAACCAAGACAAGATGAGAG 960
 QY 966 GACTTTCAG 1025
 DB 961 GACTTTCAG 1020
 QY 1026 CAGCCCTAATTAACCACTCTTCTTCTGAGGAGAGAGAGAGAGAGAGAGAG 1085
 DB 1021 CAGCCCTAATTAACCACTCTTCTTCTGAGGAGAGAGAGAGAGAGAGAGAG 1080
 QY 1086 GAGGCTGAGTGGAGTCAAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1145
 DB 1081 GAGGCTGAGTGGAGTCAAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1140
 QY 1146 TCTGCTGGAGATCTTCAACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1205
 DB 1141 TCTGCTGGAGATCTTCAACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1200
 QY 1206 GCTGGGCTCTGTGCTAATTTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1265
 DB 1201 GCTGGGCTCTGTGCTAATTTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1260
 QY 1266 CACCAAGATCTCTCCCAACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1325
 DB 1261 CACCAAGATCTCTCTCTCTGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1320
 QY 1326 CCAAGATTAACCTCTCTCTGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1385

Db 1506 AACAGTTCAGAGGACGCGGTGCGAGGTTCTCCAGCTCCAGATCCCTCGGTGAG 1565
 QY 345 TCCGAATACCTGATATACCTTTTGAAGTGAAGCCGCCCACTGTCGTGCTCAAC 404
 Db 1566 TCCGAATACCTGATATACCTTTTGAAGTGAAGCCGCCCACTGTCGTGCTCAAC 1625
 QY 405 CAGACGAGAGATCTGAGTGCMAATGCGATACAGCTGCCCCCTCATGCCCA 464
 Db 1626 CAGACGAGAGATCTGAGTGCMAATGCGATACAGCTGCCCCCTCATGCCCA 1685
 QY 465 CTGATCTGAAATGATGAGTGCATCTGGAAGAGAGGGGGCGGAACAGACCTATT 524
 Db 1686 CTGATCTGAAATGATGAGTGCATCTGGAAGAGAGGGGGCGGAACAGACCTATT 1745
 QY 525 CCAAGTACTCCCAATGCGCAGCAAGTGCAGATCACTTCCAGCCAGCTGCGAGCAAC 584
 Db 1746 CCAAGTACTCCCAATGCGCAGCAAGTGCAGATCACTTCCAGCCAGCTGCGAGCAAC 1805
 QY 585 CACTGCTCAGTGCAGAACCATCTACAGTTCAGTTCGCCGAATACAGACAGTCTCT 644
 Db 1806 CACTGCTCAGTGCAGAACCATCTACAGTTCAGTTCGCCGAATACAGACAGTCTCT 1865
 QY 645 AAGCCCACTGCTTCTTCTGCTGAGTGCAGAGTCCAGAGCAATCGGCTTT 691
 Db 1866 AAGCCCACTGCTTCTTCTGCTGAGTGCAGAGTCCAGAGCAATCGGCTTT 1912

RESULT 8
 ABQ73080
 ID ABQ73080 standard: cDNA: 1422 BP.
 AC ABQ73080
 DT 25-SBP-2002 (first entry)
 XX Zcytor19 and Fc4 fusion protein encoding cDNA SEQ ID NO:22.
 XX

Human: zcytor19; cytokine receptor; immunosuppressive; cytostatic;
 anti-leukemic; anti-arthritic; neuroprotective; anti-inflammation;
 anti-diabetic; nephrotropic; dermatological; anti-HIV; haemostatic;
 vaccine; immune system; T-cell specific leukemia; lymphoma; lupus;
 autoimmune disease; rheumatoid arthritis; multiple sclerosis; HIV;
 diabetes mellitus; inflammatory bowel disease; Crohn's disease; asthma;
 immunologic renal disease; glomerulonephritis; vasculitis; polyarteritis;
 mesangiolipidiferative disease; chronic lymphocytic leukemia; bronchitis;
 secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma;
 haemolytic uraemic syndrome; renal neoplasm; urological neoplasm;
 CM emphysema; chronic airway disease; chromosome 1; chromosome 1p36.11;
 KM gene; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX

Key Location/Qualifiers
 FT 1..1422
 FT /*tag= a
 FT /product= "zcytor19-Fc4 fusion protein"
 XX
 XX NO200244209-A2.
 XX
 XX 06-JUN-2002.
 XX
 XX 28-NOV-2001; 2001MO-US44808.
 XX
 XX 28-NOV-2000; 2000US-253561P.
 XX
 XX 07-FEB-2001; 2001US-267211P.
 XX
 XX (ZYMO) ZYMOGENETICS INC.
 XX
 XX Presnell SR, Xu W, Novak JE, Whitmore TE, Grant FJ,
 XX MPI, 2002-527700/56.
 XX
 XX P-PSDB; ABB81645.
 DE

XX Novel Zcytor19 polypeptides and polynucleotides useful for stimulating
 PT immune responses in animals for producing antibodies, and for treating
 PT autoimmune diseases, leukemia and asthma.
 XX
 XX Example 4; Page 182-184; 2000p; English.
 PS
 XX The present invention describes an isolated human zcytor19 protein (I),
 CC and truncated zcytor19 proteins. (I) has immunosuppressive, cytostatic,
 CC anti-neuritic, anti-arthritic, neuroprotective, anti-inflammatory,
 CC anti-diabetic, nephrotropic, dermatological, anti-HIV and haemostatic
 CC activities, and can be used in vaccines. (I) or an antibody binding (I)
 CC can be used for suppressing the immune system for reducing rejection of
 CC tissue or organ transplants and grafts and for treating T-cell specific
 CC leukemias or lymphomas and autoimmune diseases including rheumatoid
 CC arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel
 CC disease and Crohn's disease. The antibodies can also be used for treating
 CC immunologic renal diseases, glomerulonephritis, mesangiolipidiferative
 CC disease, chronic lymphocytic leukemia, secondary glomerulonephritis or
 CC vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related
 CC diseases, amyloidosis and haemolytic uraemic syndrome. (I) and the
 CC antibodies can also be used for renal or urological neoplasms and
 CC multiple myelomas, asthma, bronchitis, emphysema and other chronic
 CC airway diseases. Human zcytor19 is located to chromosome 1, more
 CC specifically to chromosome 1p36.11. The present sequence encodes a human
 CC zcytor19-Fc4 fusion protein from the present invention.
 XX

Seq Sequence 1422 BP; 331 A; 451 C; 377 G; 263 T; 0 other;
 Query Match 38.0%; Score 607.4; DB 24; Length 1422;
 Best Local Similarity 99.7%; Pred. No. 3,4e-147;
 Matches 619; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 67 AGGCCCCGTCTGAGCCCTCCAGAAATGATGACCTGCTCCAGAACTTACGCGTAC 126
 Db 109 AGGCCCCGTCTGAGCCCTCCAGAAATGATGACCTGCTCCAGAACTTACGCGTAC 168
 QY 127 CTGATGAGTCTCCAGAGCTTGGCAACCCAGATGTACCTATTGTTGGCC ATAG 185
 Db 169 CTGATGAGTCTCCAGAGCTTGGCAACCCAGATGTACCTATTGTTGGCC ATAG 228
 QY 186 AGCTCTCCAGCCCGTAGACGCTGCGGAGAGTGAAGTGTGCGGAAACCAAGAGCTG 245
 Db 229 AGCTCTCCAGCCCGTAGACGCTGCGGAGAGTGAAGTGTGCGGAAACCAAGAGCTG 288
 QY 246 CTATGTTCTATGATGCTGCTGAAAGAAACAGACCTGTACCAAGTTCAAGGACGCTG 305
 Db 289 CTATGTTCTATGATGCTGCTGAAAGAAACAGACCTGTACCAAGTTCAAGGACGCTG 348
 QY 306 CGAGCGGTTTCTCCAGTCCAGATGCTCCCTGGTGGAGTCCGAATACCTGATTAACCTT 365
 Db 349 CGAGCGGTTTCTCCAGTCCAGATGCTCCCTGGTGGAGTCCGAATACCTGATTAACCTT 408
 QY 366 TTGGAAGTGAAGCGGCGCCCACTGTCTGTGCTACCCAGAGAGAGTCTGAGT 425
 Db 409 TTGGAAGTGAAGCGGCGCCCACTGTCTGTGCTACCCAGAGAGAGTCTGAGT 468
 QY 426 GCCAATGCCAGTACCAAGTCCCTCCCTGATGCCCACTGATCTGAAGTAGAGTG 485
 Db 469 GCCAATGCCAGTACCAAGTCCCTCCCTGATGCCCACTGATCTGAAGTAGAGTG 528
 QY 486 GCATTCTGAAAGAGAGGGGCGGAAACAGACCTATTTCAGTCACTGCCAGTCCAG 545
 Db 529 GCATTCTGAAAGAGAGGGGCGGAAACAGACCTATTTCAGTCACTGCCAGTCCAG 588
 QY 546 CCAAGTCAATCACTCTCCAGAGCTGCGAGGAAACACATCTGCTCAGTCCAGAAC 605
 Db 589 CCAAGTCAATCACTCTCCAGAGCTGCGAGGAAACACATCTGCTCAGTCCAGAAC 648
 QY 606 ATCTACAGTTCAGTGTCCGAAATACAGCAAGTCTTAAGCCCACTGCTTCTGCTG 665
 Db 649 ATCTACAGTTCAGTGTCCGAAATACAGCAAGTCTTAAGCCCACTGCTTCTGCTG 708

QY 666 GAGCTCCGAGAGCAACTGG 686
 DB 709 GAGCTCCGAGAGCAACTGG 729

RESULT 9
 ABQ73079
 ID ABQ73079 standard; cDNA; 673 BP.
 XX

AC ABQ73079;

DT 25-SEP-2002 (first entry)

DE Human truncated soluble zcytor19 encoding cDNA SEQ ID NO:20.

XX
 KM Human; zcytor19; cytokine receptor; immunosuppressive; cytostatic;
 KM antirheumatic; antiallergic; neuroprotective; anti-inflammatory;
 KM antidiabetic; nephrotoxic; dermatological; anti-HIV; haemostatic;
 KM vaccine; immune system; T-cell specific leukemia; lymphoma; lupus;
 KM autoimmune disease; rheumatoid arthritis; multiple sclerosis; HIV;
 KM diabetes mellitus; inflammatory bowel disease; Crohn's disease; asthma;
 KM immunologic renal disease; glomerulonephritis; vasculitis; polyarteritis;
 KM mesangiolipolytic disease; chronic lymphocytic leukemia; bronchitis;
 KM secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma;
 KM haemolytic uraemic syndrome; renal neoplasm; urological neoplasm;
 KM emphysema; chronic airway disease; chromosome 1; chromosome 1p36.11;
 KM gene; ss.

XX Homo sapiens.

PH Key Location/Qualifiers

FT CDS

FT 1..636
 FT /tag= a
 FT /product= "truncated soluble zcytor19"

FT sig_peptide

FT 1..60
 FT /tag= b
 FT /tag= 61..633
 FT /product= "mature truncated soluble zcytor19"

FT mat_peptide

FT 1..60
 FT /tag= c
 FT /product= "mature truncated soluble zcytor19"

FT WO200244209-A2.

XX 06-JUN-2002.

XX 28-NOV-2001; 2001WO-US44808.

XX 28-NOV-2000; 2000US-253561P.

XX 07-FEB-2001; 2001US-267211P.

XX (ZYMO) ZYMOGENETICS INC.

XX Prenell SR, Xu W, Novak JE, Whitmore TE, Grant RJ;

XX MPI; 2002-527700/56.

XX P-PDB; ABB81644.

XX Novel zcytor19 polypeptides and polynucleotides useful for stimulating

XX immune responses in animals for producing antibodies, and for treating

XX autoimmune diseases, leukemia and asthma

XX Claim 2; Page 179-181; 200pp; English.

XX The present invention describes an isolated human zcytor19 protein (1),
 CC and truncated zcytor19 proteins. (1) has immunosuppressive, cytostatic,
 CC antirheumatic, antiallergic, neuroprotective, anti-inflammatory,
 CC antidiabetic, nephrotoxic, dermatological, anti-HIV and haemostatic
 CC activities, and can be used in vaccines, (1) or an antibody binding (1)
 CC can be used for suppressing the immune system for reducing rejection of
 CC tissue or organ transplants and grafts and for treating T-cell specific
 CC leukemias or lymphomas and autoimmune diseases including rheumatoid
 CC arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel
 CC disease and Crohn's disease. The antibodies can also be used for treating
 CC immunologic renal diseases, glomerulonephritis, mesangiolipolytic

CC disease, chronic lymphocytic leukemia, secondary glomerulonephritis or
 CC vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related
 CC diseases, amyloidosis and haemolytic uraemic syndrome. (1) and the
 CC antibodies can also be used for renal or urological neoplasms and
 CC multiple myelomas, asthma, bronchitis, emphysema and other chronic
 CC airway diseases. Human zcytor19 is located to chromosome 1, more
 CC specifically to chromosome 1p36.11. The present sequence encodes a human
 CC truncated soluble zcytor19 protein from the present invention.

XX SQ Sequence 673 BP; 127 A; 223 C; 182 G; 141 T; 0 other;

Query Match 31.1%; Score 498; DB 24; Length 673;

Best Local Similarity 99.8%; Pred. No. 5,8e-119; Matches 509; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 7 ATGCGGGGCGCGAGCGCTGGGGCCCCCTGCTCTGCTGCTGCGAGCGCTTCAGGG 66

DB 1 ATGCGGGGCGCGAGCGCTGGGGCCCCCTGCTCTGCTGCTGCGAGCGCTTCAGGG 60

QY 67 AGGCGCGCTGCGCGCTTCGCCAGATGACGCTCTCCAGAGCTTCAGCGTGAC 126

DB 61 AGGCGCGCTGCGCGCTTCGCCAGATGACGCTCTCCAGAGCTTCAGCGTGAC 120

QY 127 CTGACATGCGCTCCAGCGCTTCGCAACCCCGAGATGACCTTATTTGTGGCC-ATCAG 185

DB 121 CTGACATGCGCTCCAGCGCTTCGCAACCCCGAGATGACCTTATTTGTGGCC-ATCAG 180

QY 186 AGCTCTCCACCCGATGACGCTGCGCGAGTGAAGATGTGCGGAAACCAAGAGCTG 245

DB 181 AGCTCTCCACCCGATGACGCTGCGCGAGTGAAGATGTGCGGAAACCAAGAGCTG 240

QY 246 CTATGCTCTATGATGCTGCTGATGAAGACAGACTCTTCAACAACTTCAAGGACGCTG 305

DB 241 CTATGCTCTATGATGCTGCTGATGAAGACAGACTCTTCAACAACTTCAAGGACGCTG 300

QY 306 CGAGCGGTTTCTCCAGCTTCACAGTCCCTCGGATGAGTCCGAATACCTGATTAACCTT 365

DB 301 CGAGCGGTTTCTCCAGCTTCACAGTCCCTCGGATGAGTCCGAATACCTGATTAACCTT 360

QY 366 TTGAGATGAGACCGGCGCCGACCTGCTGAGTGTCAACCAAGAGAGATCTGAGT 425

DB 361 TTGAGATGAGACCGGCGCCGACCTGCTGAGTGTCAACCAAGAGAGATCTGAGT 420

QY 426 GCCAATGCCACGATACAGCTGCCCCCTGAGTCCCACTGATCTGATGATGAGTG 485

DB 421 GCCAATGCCACGATACAGCTGCCCCCTGAGTCCCACTGATCTGATGATGAGTG 480

QY 486 GCATTCGAGAGAGAGGAGCGGAAACAG 515

DB 481 GCATTCGAGAGAGAGGAGCGGAAACAG 510

RESULT 10

AD50488
 ID AD50488 standard; cDNA; 674 BP.

XX AD50488;

XX 24-MAR-2003 (first entry)

XX Human zcytor19 truncated soluble receptor cDNA.

XX Human; leukemia; carcinoma; acquired immune deficiency syndrome; AIDS;

XX melanoma; Kaposi's sarcoma; multiple myeloma; non-Hodgkin's lymphoma;

XX hepatitis; infection; myocardiitis; blood vessel formation; gene therapy;

XX growth regulation; developmental processes; immunotherapy; zcytor19; gene;

XX receptor; ss.

XX Homo sapiens.

OS Key Location/Qualifiers

PH CDS

FT 1..636
 FT /tag= a

```

FT      sig_peptide      /product= "Human zcytor19 truncated soluble receptor"
FT      1..60
FT      mat_peptide      /*tag= b
FT      61..633
FT      /*tag= c
FT      /product= "Mature human zcytor19 truncated soluble
FT      receptor"
XX      WO200286087-A2.
XX      31-OCT-2002.
XX      19-APR-2002; 2002WO-US12887.
XX      20-APR-2001; 2001US-285408P.
XX      20-APR-2001; 2001US-285424P.
XX      25-APR-2001; 2001US-286482P.
XX      29-JUN-2001; 2001US-0895834.
XX      22-OCT-2001; 2001US-341050P.
XX      22-OCT-2001; 2001US-341105P.
XX      (ZYMO ) ZYMOGENETICS INC.
XX      Sheppard PO, Fox BA, Klucher KM, Taft DM, Kindavogel WR;
XX      WPI, 2003-093122/08.
XX      P-PSDB; AAE32768.
XX      New zcyto20, zcyto21, zcyto22, zcyto24 and zcyto25 polypeptides and
XX      polynucleotides useful for treating leukemia, carcinoma, malignant
XX      melanoma, AIDS-related Kaposi's sarcoma, myeloma, non-Hodgkin's
XX      lymphoma, hepatitis and infections
XX      Example 30; Page 147-148; 160pp; English.
XX      The invention relates to zcyto20, zcyto21, zcyto22, zcyto24 and zcyto25
XX      polypeptides and polynucleotides. Sequences of the invention are useful
XX      for treating hairy cell leukemia, renal cell or basal cell carcinoma,
XX      malignant melanoma, AIDS-related Kaposi's sarcoma, multiple myeloma,
XX      non-Hodgkin's lymphoma, hepatitis B, C or D, infections (e.g. bacterial,
XX      fungal or protozoal) or myocarditis. The invention is useful for growth
XX      regulation in the liver, blood vessel formation and other developmental
XX      processes. The invention is also useful in immunotherapy and gene
XX      therapy. The present sequence is human zcytor19 truncated soluble
XX      receptor cDNA.
XX      Sequence 674 BP; 128 A; 223 C; 182 G; 141 T; 0 other;
XX      Query Match      31.1%; Score 498; DB 25; Length 674;
XX      Best Local Similarity 99.8%; Pred. No. 5.8e-119;
XX      Matches 509; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
QY      7      ATGGCGGGGCGGAGGCGTGGGGGCGCCCTGCTCTGTGCGTGTCTGACAGGCGGCTCCAGGG      66
DB      1      ATGGCGGGGCGGAGGCGTGGGGGCGCCCTGCTCTGTGCGTGTCTGACAGGCGGCTCCAGGG      60
QY      67      AGGCGCCCGTGTGGCCCTTCCCAAGATGTAGCGCTGTCTCCCAAGACTTCAAGCGTGTAC      126
DB      61      AGGCGCCCGTGTGGCCCTTCCCAAGATGTAGCGCTGTCTCCCAAGACTTCAAGCGTGTAC      120
QY      127      CTGACATGTGCTCCAGGCGTGTGGCAACCCCAAGATGTAGCTATTTTGTGGCC-ATCAG      185
DB      121      CTGACATGTGCTCCAGGCGTGTGGCAACCCCAAGATGTAGCTATTTTGTGGCCATACAG      180
QY      186      AGCTTCCCAACCCGTTAGAGCGTGGCGGAGATGTAGAGATGTGGCGGAAACCAAGAACTG      245
DB      181      AGCTTCCCAACCCGTTAGAGCGTGGCGGAGATGTAGAGATGTGGCGGAAACCAAGAACTG      240
QY      246      CTATGTTCTATGATGTGCTGTAGAGAAACAGAGACTGTGACACAGATTCAAGGGACGGGTG      305
DB      241      CTATGTTCTATGATGTGCTGTAGAGAAACAGAGACTGTGACACAGATTCAAGGGACGGGTG      300
QY      306      CGAGCGTTTCTCCAGCTCCAGATGCCCGCGGTGGATGCGAATACCTGATTAACCTT      365

```

```

DB      301      CGAGCGGTTTCTCCAGCTCCAGATCCCTCGGAGTGGAGTCCGAATCCTGGAATACCTT      360
QY      366      TTGGAAGTGAAGCGGCGCCACCTGTCTGTGTCTCAACCAAGAGAGATCCTGACT      425
DB      361      TTGGAAGTGAAGCGGCGCCACCTGTCTGTGTCTCAACCAAGAGAGATCCTGACT      420
QY      426      GCCAATGCGCATGTCACAGCTGCGCCCTCGCATAGCCCCCACTGATCTGAAGTATGAGGTG      485
DB      421      GCCAATGCGCATGTCACAGCTGCGCCCTCGCATAGCCCCCACTGATCTGAAGTATGAGGTG      480
QY      486      GCATTCTGGAAGAGAGGCGGCGCGGAAACAAG      515
DB      481      GCATTCTGGAAGAGAGGCGGCGCGGAAACAAG      510
RESULT 11
ID      AAD35324 standard; DNA; 704 BP.
XX      AAD35324;
AC      25-JUL-2002 (first entry)
XX      Human (DNAX interferon like receptor subunit 4) DIRS4 DNA.
XX      Human; morphogenesis; DNAX interferon like receptor subunit 4; DIRS4;
XX      immune system; cytokine receptor; tumour necrosis factor; TNF; TNF;
XX      toll like receptor like molecule; TLR-L; transforming growth factor;
XX      TGF $\alpha$ ; 56856; claudin; schlaefen; gene therapy; vaccine; immunological;
XX      medical disorder; gene; db.
XX      Homo sapiens.
FH      Key      Location/Qualifiers
FT      CDS      1..636
FT      /tag= a
FT      /product= "Human DIRS4 protein"
XX      WO200220569-A2.
XX      14-MAR-2002.
XX      07-SEP-2001; 2001WO-US28013.
XX      08-SEP-2000; 2000US-231267P.
XX      (SCHE ) SCHERING CORP.
XX      Parham CL, Gorman DM, Kurata H, Arai N, Sana TR, Matison JD,
XX      Murphy EE, Savkoor C, Grein J, Smith KM, Mcclanahan TK;
XX      WPI; 2002-362239/39.
XX      P-PSDB; AAE22212.
XX      Recombinant polypeptide for immunizing a subject, comprises
XX      non-overlapping segments of amino acids identical to cytokine receptor
XX      sequences
XX      Claim 16; Page 95-96; 21pp; English.
XX      The present invention relates to compositions and methods for affecting
XX      mammalian physiology, including morphogenesis or immune system function.
XX      The invention particularly relates to recombinant polypeptides comprising
XX      3 distinct non-overlapping segments of four amino acids identical to
XX      cytokine receptors, e.g., cytokine receptor like molecular structures
XX      such as segments of the sequences of DNAX interferon like receptor
XX      subunit 4 (DIRS4), tumour necrosis factor (TNF $\alpha$  or TNF $\beta$ ), toll like
XX      receptor like molecules (TLR-L1 through TLR-L5), transforming growth
XX      factor (TGF $\alpha$ ), 56856, claudin and schlaefen. Sequences of the invention
XX      are used to modulate physiology or development of a cell. They are also
XX      used in gene therapy and as vaccines. Nucleic acid sequences are useful
XX      as probes for detecting a level of respective genes or transcripts in

```


Oy 426 GCACATGACAGTGCACGATGCCCCCGATGATGCCCCCATGAGTCTGAAATGAGAGTGG 485
 Db 421 GCMAATGCMACNTATYCAATYTCNCATCCTGATGCGCNCATYTAATGATTAATGAGATN 480
 Oy 486 GCATCTTGGAAGAGGGGGCCGGAACAAGACCTTATTTCAATCACTCTCCCATGGCC 543
 Db 481 GCATYTTGGAAAGARGGGNGCNGMAATYAAGTNGGNNMNSNTTYCCNGCNCNCMMGY 538
 RESULT 13
 ID AAF64460
 AC AAF64460 standard; CDNA; 374 BP.
 XX AAF64460;
 AC AAF64460;
 DT 09-APR-2001 (first entry)
 XX Novel human polynucleotide, SEQ ID NO: 216.
 DE Novel human polynucleotide, SEQ ID NO: 216.
 XX Human; cytosolic; gene therapy; colon cancer; prostate cancer;
 KM breast cancer; lung cancer; cancer detection; ss.
 KM Homo sapiens.
 OS Homo sapiens.
 XX MO200102568-A2.
 XX 11-JAN-2001.
 PD 30-JUN-2000; 2000WO-US18374.
 PF 02-JUL-1999; 98US-0142310.
 PR 02-JUL-1999; 98US-0142311.
 PA (CHIR) CHIRON CORP.
 PA (HYSE-) HYSEQ INC.
 PA Williams LT, Escobedo J, Imiti NA, Garcia PD, Klingner J, Kassam A;
 PI Reinhard C, Randazzo F, Kennedy GC, Pot D, Lamson G, Dmanac R;
 PI Ckenjakov R, Dmanac S, Dickson M, Labat I, Leshowitz D;
 PI Kila D, Garcia V, Jones LW, Strache-Crain B;
 DR WPI, 2001-091805/10.
 XX Library of polynucleotides for diagnosing a cancerous state of a
 PT mammalian cell and detecting cancer, particularly of the colon or
 PT prostate, comprises 3351 human polynucleotide sequences -
 XX claim 9; Page 575; 1046pp; English.
 CC The present sequence is one of 3351 sequences in a library of human
 CC polynucleotides. The library is used to detect differentially expressed
 CC genes correlated with a cancerous state of a mammalian cell and can
 CC detect colon, prostate, breast and lung cancer. The library can be used
 CC to produce probes for detection of mRNA and to produce additional copies
 CC of the polynucleotide. The probes can be used for chromosome mapping of
 CC the polynucleotide and for detection of transcription levels. Ribozymes
 CC or antisense oligonucleotides can be generated. The polynucleotides and
 CC their gene products are used as genetic or biochemical markers (e.g. in
 CC blood or tissues) that will detect the earliest changes along the
 CC carcinogenesis pathway and/or monitor the efficacy of therapies and
 CC preventive interventions. The polynucleotides, polypeptides and
 CC antibodies against them can be used in pharmaceutical compositions to
 CC treat the cancers and proliferative disorders such as neoplasia,
 CC dysplasia and hyperplasia.
 CC SQ Sequence 374 BP; 71 A; 117 C; 107 G; 79 T; 0 other;
 Query Match 21.0%; Score 335.4; DB 22; Length 374;
 Best Local Similarity 95.4%; Pred. No. 6.3e-77;
 Matches 356; Conservative 0; Mismatches 16; Indels 1; Gaps 1
 23 GCTGGAGCCCTCTGCTCTGCTCTGCTCTGACAGCCGCTTCAGAGAGCCCGCTGTGCCCC 82

Dd	2	GCAGAGAGCCCTCTGTTCTCTGTGCTCTGTCAGAGCGCTCCAGGGAGAGCCCGTCTGGCC	61
Qy	83	CTCCCCAGATATGACGCTGCTCTCCCGAAGCTTCAACGTGTACCTGACATAGGCTCCAG	144
Dd	62	CTCCCCAGAAATGACGCTGCTCTCCCGAAGCTTCAAGCGGGATACCTGACATAGGCTCCAG	122
Qy	143	GGCTTGGCAACCCCCAGAGATGTGACCTATTTTGTGGCC-ATCAGAGCTCTCCACCGTA	201
Dd	122	GGCTTGGCAACCCCCAGAGATGTGACCTATTTTGTGGCCATCAGAGCTCTCCACCGTA	181
Qy	202	GACGGTGGCGGAAGTGAAGAGTGTGGGGGACCAAGAGAGCTGTATGTCTATAGATG	261
Dd	182	GACGGTGGCGGAAGTGAAGAGTGTGGGGGACCAAGAGAGCTGTATGTCTATAGATG	241
Qy	262	GCTGTAGAAACAGACCTGTACCAACAGTTCAAGGAGCGGTGGGACGGTTCTCCCA	322
Dd	242	GCTGTAGAAACAGACCTGTACCAACAGTTCAAGGAGCGGTGGGACGGTTCTCCCA	302
Qy	322	GCTCCAGTGGCCCTGGTGGAGTCCGAATACCTGTATCTTTTGAAGTGAAGCCGG	381
Dd	302	GCTCCAGTGGCCCTGGTGGAGTCCGAATACCTGTATCTTTTGAAGTGAAGCCGG	361
Qy	382	CCCCACCTGTCTCT 394	
Dd	362	CCCCACCTGTCTCT 374	
RESULT 14.			
ID	AAf65622/c	AAf65622 standard; cDNA, 392 BP.	
XX	AAf65622;		
DT	09-APR-2001	(first entry)	
DE	Novel human polynucleotide, SEQ ID NO: 1378.		
XX			
KW	Human; cytostatic; gene therapy; colon cancer; prostate cancer;		
KM	breast cancer; lung cancer; cancer detection; ss.		
OS	Homo sapiens.		
XX			
PN	WO200102568-A2.		
XX			
PD	11-JAN-2001.		
XX			
FP	30-JUN-2000; 2000MO-US18374.		
XX			
PR	02-JUL-1999; 99US-0142310.		
XX	02-JUL-1999; 99US-0142311.		
XX	(CHIR) CHIRON CORP.		
PA	(HYSE-) HYSEQ INC.		
XX			
PI	Williams LT, Escobedo J, Innis MA, Garcia PD, Klinger J, Kasam A,		
PI	Reinhard C, Randazzo P, Kennedy GC, For D, Lamson G, Drmanac R,		
PI	Cherkasov R, Drmanac S, Dickson M, Labat I, Leshkowitz D,		
PI	Kita D, Garcia V, Jones LM, Strache-Grain B;		
XX			
DR	WPI; 2001-091805/10.		
XX			
PT	Library of polynucleotides for diagnosing a cancerous state of a		
PT	mammalian cell and detecting cancer, particularly of the colon or		
PT	prostate, comprises 351 human polynucleotide sequences -		
XX			
PS	claim 9; Page 741; 1046pp; English.		
CC	The present sequence is one of 351 sequences in a library of human		
CC	polynucleotides. The library is used to detect differentially expressed		
CC	genes correlated with a cancerous state of a mammalian cell and can		
CC	detect colon, prostate, breast and lung cancer. The library can be used		
CC	to produce probes for detection of mRNA and to produce additional copies		

CC of the polynucleotides. The probes can be used for chromosome mapping of
CC the polynucleotide and for detection of transcription levels. Ribozymes
CC or antisense oligonucleotides can be generated. The polynucleotides and
CC their gene products are used as genetic or biochemical markers (e.g. in
CC blood or tissues) that will detect the earliest changes along the
CC carcinogenesis pathway and/or monitor the efficacy of therapies and
CC preventive interventions. The polynucleotides, polypeptides and
CC antibodies against them can be used in pharmaceutical compositions to
CC treat the cancers and proliferative disorders such as neoplasia,
CC dysplasia and hyperplasia.

XX Sequence 392 BP; 76 A; 78 C; 132 G; 106 T; 0 other;

Query Match 10.3%; Score 165; DB 22; Length 392;
Best Local Similarity 97.1%; Pred. No. 9.1e-33;
Matches 168; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 510 AACAGACCTATTTCAGTCACTCCCGATGCGGACGATCACTCTCCAGCA 569
DB 207 AACAGACCTATTTCAGTCACTCCCGATGCGGACGATCACTCTCCAGCA 148
QY 570 GCTGCCAGGACACCACTGCTCTGAGGACCAATCTACAGTTCCAGTCCGAAA 629
DB 147 GCTGCCAGGACACCACTGCTCTGAGGACCAATCTACAGTTCCAGTCCGAAA 88
QY 630 TACAGCAAGTTCTCTAAGCCCACTGCTCTTGTGAGAGGTCCAGAGCGAA 682
DB 87 TACAGCAAGTTCTCTAAGCCCACTGCTCTTGTGAGAGGTCCAGAGCGAA 35

RESULT 15

AAF65522/c
ID AAF65522 standard; cDNA; 382 BP.

XX AAF65522;

AC AAF65522;

DT 09-APR-2001 (first entry)

XX Novel human polynucleotide, SEQ ID NO: 1278.

XX Human; cytostatic; gene therapy; colon cancer; prostate cancer;

XX breast cancer; lung cancer; cancer detection; ss.

XX Homo sapiens.

XX WO200102568-A2.

XX 11-JAN-2001.

XX 30-JUN-2000; 2000WO-US18374.

XX 02-JUL-1999; 99US-0142310.

XX 02-JUL-1999; 99US-0142311.

XX (CHIR) CHIRON CORP.

XX (HSE-) HXSEQ INC.

XX Williams LT, Escobedo J, Innis MA, Garcia PD, Klinger J, Kassam A;
XX Reinhard C, Randazzo F, Kennedy GC, Pot D, Lamson G, Dymanc R;
XX Cirenjakov R, Dymanc S, Dickson M, Labat I, Leshkowitz D;
XX Kila D, Garcia V, Jones LM, Strache-Crain B;

XX WPI; 2001-091805/10.

XX Library of polynucleotides for diagnosing a cancerous state of a
XX mammalian cell and detecting cancer, particularly of the colon or
XX prostate, comprises 3351 human polynucleotide sequences -

XX Claim 9; Page 727; 1046pp; English.

XX The present sequence is one of 3351 sequences in a library of human
XX polynucleotides. The library is used to detect differentially expressed
XX genes correlated with a cancerous state of a mammalian cell and can

CC detect colon, prostate, breast and lung cancer. The library can be used
CC to produce probes for detection of mRNA and to produce additional copies
CC of the polynucleotides. The probes can be used for chromosome mapping of
CC the polynucleotide and for detection of transcription levels. Ribozymes
CC or antisense oligonucleotides can be generated. The polynucleotides and
CC their gene products are used as genetic or biochemical markers (e.g. in
CC blood or tissues) that will detect the earliest changes along the
CC carcinogenesis pathway and/or monitor the efficacy of therapies and
CC preventive interventions. The polynucleotides, polypeptides and
CC antibodies against them can be used in pharmaceutical compositions to
CC treat the cancers and proliferative disorders such as neoplasia,
CC dysplasia and hyperplasia.

XX Sequence 382 BP; 77 A; 77 C; 130 G; 98 T; 0 other;

Query Match 10.2%; Score 163.4; DB 22; Length 382;
Best Local Similarity 96.5%; Pred. No. 2.3e-32;
Matches 167; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 510 AACAGACCTATTTCAGTCACTCCCGATGCGGACGATCACTCTCCAGCA 569
DB 207 AACAGACCTATTTCAGTCACTCCCGATGCGGACGATCACTCTCCAGCA 148
QY 570 GCTGCCAGGACACCACTGCTCTGAGGACCAATCTACAGTTCCAGTCCGAAA 629
DB 147 GCTGCCAGGACACCACTGCTCTGAGGACCAATCTACAGTTCCAGTCCGAAA 88
QY 630 TACAGCAAGTTCTCTAAGCCCACTGCTCTTGTGAGAGGTCCAGAGCGAA 682
DB 87 TACAGCAAGTTCTCTAAGCCCACTGCTCTTGTGAGAGGTCCAGAGCGAA 35

Search completed: September 17, 2003, 18:50:40
Job time : 315.324 secs